{
    "id": 11084,
    "fullName": "CD74 - NTRK1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CD74-NTRK1 results from the fusion of CD74 and NTRK1 and leads to constitutive kinase activity of Ntrk1 and induces tumor formation in xenograft models (PMID: 24162815).",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 972,
        "geneSymbol": "CD74",
        "terms": [
            "CD74",
            "DHLAG",
            "HLADG",
            "Ia-GAMMA",
            "II",
            "p33"
        ]
    },
    "variant": "CD74 - NTRK1",
    "createDate": "08/31/2015",
    "updateDate": "08/31/2015",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4914,
                "geneSymbol": "NTRK1",
                "terms": [
                    "NTRK1",
                    "MTC",
                    "p140-TrkA",
                    "TRK",
                    "Trk-A",
                    "TRK1",
                    "TRKA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 9719,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-536924 inhibited NTRK1 phosphorylation and growth of transformed cells expressing CD74-NTRK1 in culture (PMID: 27370605).",
            "molecularProfile": {
                "id": 11128,
                "profileName": "CD74 - NTRK1"
            },
            "therapy": {
                "id": 683,
                "therapyName": "BMS-536924",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3021,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lestaurtinib (CEP-701) inhibited cell growth, colony formation, Ntrk1 phosphorylation, and downstream signaling of transformed cells expressing CD74-NTRK1 in culture (PMID: 24162815).",
            "molecularProfile": {
                "id": 11128,
                "profileName": "CD74 - NTRK1"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3020,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vitrakvi (larotrectinib) inhibited cell growth, colony formation, Ntrk1 phosphorylation, and downstream signaling of transformed cells expressing CD74-NTRK1 in culture (PMID: 24162815).",
            "molecularProfile": {
                "id": 11128,
                "profileName": "CD74 - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3022,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited cell growth, colony formation, Ntrk1 phosphorylation and downstream signaling of transformed cells expressing CD74-NTRK1 in culture (PMID: 24162815).",
            "molecularProfile": {
                "id": 11128,
                "profileName": "CD74 - NTRK1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3552,
                    "pubMedId": 24162815,
                    "title": "Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11128,
            "profileName": "CD74 - NTRK1",
            "profileTreatmentApproaches": [
                {
                    "id": 19347,
                    "name": "Larotrectinib",
                    "profileName": "CD74 - NTRK1"
                },
                {
                    "id": 6445,
                    "name": "Crizotinib",
                    "profileName": "CD74 - NTRK1"
                },
                {
                    "id": 6446,
                    "name": "Trk Receptor Inhibitor (Pan)",
                    "profileName": "CD74 - NTRK1"
                },
                {
                    "id": 6447,
                    "name": "TrkA Receptor Inhibitor",
                    "profileName": "CD74 - NTRK1"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}